Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on May 29, 2025. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol "CTXR". The report addresses a regulatory determination regarding the Company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a listing compliance issue related to the Company's stock price.
Material Changes and Listing Status
On May 29, 2025, the Company received a determination letter from the Nasdaq Listing Qualifications Department stating it is not in compliance with Nasdaq Listing Rule 5550(a)(2). The non-compliance is due to the closing bid price of the Company's common stock remaining below the minimum requirement of $1.00 per share for 33 consecutive business days. Because the Company effected a reverse stock split within the prior one-year period, it is ineligible for the standard compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv).
Outlook, Management Commentary, and Risks
- Appeal Process: The Company intends to timely request an appeal of the determination by June 5, 2025. This appeal will stay the suspension and delisting pending a decision by the Nasdaq Hearings Panel.
- Delisting Timeline: If the Company fails to request a hearing, trading of its common stock is scheduled for delisting at the opening of business on June 9, 2025.
- Compliance Plan: The Company intends to submit a plan to the Panel to regain compliance.
- Risks: There is no assurance that the Panel will grant a compliance period or that the Company will ultimately meet the requirements for continued listing. The filing includes standard forward-looking statement disclaimers regarding these uncertainties.
Key Facts for Investor Verification
- Verify the status of the appeal request with the Nasdaq Hearings Panel by the June 5, 2025 deadline.
- Monitor the Company's stock price to assess the feasibility of regaining the $1.00 minimum bid price.
- Review the specific compliance plan the Company intends to submit to the Panel.
- Check for subsequent filings regarding the Panel's decision or any alternative listing strategies.